SCHEMBL17320463

SCHEMBL17320463

CCc1ccc(N2CCN(CC(F)F)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
REV1 Q9UBZ9 3/20 0.51
MAPT P10636 7/20 0.50
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 4/20 0.45
GFER P55789 3/20 0.45
GAA P10253 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
TSHR P16473 2/20 0.45
HTT P42858 2/20 0.45
RAD52 P43351 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
ALOX15 P16050 1/20 0.45
ALOX12 P18054 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21655007 0.85 MEN1 (0.53) MEN1KMT2AREV1MAPTALDH1A1
SCHEMBL14924480 0.83 MAPT (0.51) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL28758087 0.82 KDM4E (0.61) MEN1KMT2AREV1MAPTALDH1A1
SCHEMBL13179262 0.80 GAA (0.67) MEN1KMT2AREV1MAPTALDH1A1
SCHEMBL12826299 0.80 MAPT (0.64) MEN1KMT2AREV1MAPTALDH1A1
SCHEMBL14923964 0.80 MAPT (0.59) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL24681534 0.79 IGF1R (0.46) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL17289613 0.79 IGF1R (0.64) MAPTSMN1; SMN2TSHRALOX15L3MBTL1
SCHEMBL17450396 0.79 MAPT (0.61) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL25675612 0.79 MAPT (0.54) MAPTALDH1A1KDM4EGFERTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10259811-B2 Tank-binding kinase inhibitor compounds GILEAD SCIENCES, INC. (US) 2019-04-16 US disclosed
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 US disclosed
WO-2015187684-A1 TANK-BINDING KINASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2015-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10259811-B2 Tank-binding kinase inhibitor compounds TBKBP1, TNKS1BP1, TNKS MEN1 3091/4885KMT2A 1865/4885REV1 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.